May 21, 2018 / 1:08 PM / in 8 months

Novo Nordisk says haemophilia drug data support clinical profile

May 21 (Reuters) - A head-to-head trial showed that people with haemophilia B who received Novo Nordisk’s Refixia achieved greater total factor IX exposure than those treated with recombinant factor IX-Fc Fusion Protein, the Danish company said on Monday.

* People with haemophilia B have congenital factor IX deficiency and are either missing or have a malfunctioning factor IX protein, which is needed for proper blood clotting

* “These head-to-head data support the strong clinical profile of Refixia,” chief science officer Mads Krogsgaard Thomsen said in a press release. (Reporting by Copenhagen newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below